Nuvation Bio Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Insider Trading Arrangements
On September 11, 2026, Colleen Sjogren, the Company’s Chief Commercial Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 718,862 shares of the Company's Class A Common Stock. Pursuant to this plan, Ms. Sjogren may sell shares beginning January 10, 2027 and ending January 15, 2028.
On September 4, 2026, Moses Makunje, the Company’s Principal Accounting Officer, entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, providing for the sale of up to 451,041 shares of the Company's Class A Common Stock. Pursuant to this plan, Mr. Makunje may sell shares beginning January 3, 2027 and ending December 30, 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.